title: Editorial Comment from Dr O'Carrigan and Dr Grimison to Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
authors.affiliation: Chris O'Brien Lifehouse, Camperdown, NSW, Australia. brent.ocarrigan@sydney.edu.au.|Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia. brent.ocarrigan@sydney.edu.au.
authors.forename: Brent
authors.initials: B
authors.lastname: O'Carrigan
authors.affiliation: Chris O'Brien Lifehouse, Camperdown, NSW, Australia.|Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Grimison
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000145:classification* / Q000628:therapy*; D013736:Testicular Neoplasms / Q000145:classification* / Q000628:therapy*